Literature DB >> 24073856

In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset.

Lucia Kucerova1, Lucia Feketeova, Zuzana Kozovska, Martina Poturnajova, Miroslava Matuskova, Radim Nencka, Pavel Babal.   

Abstract

BACKGROUND: The hierarchical model of solid tumor proposes the existence of rare tumor cell subpopulations with stem-cell properties. The glycoprotein prominin-1 (CD133) represents one of the cancer stem-cell markers in several tumor types. The CD133+ cell subpopulation was shown to be enriched for tumor-initiating and highly chemoresistant cells in human cancer(s).
METHODS: We investigated whether CD133+ cells derived from human medullary thyroid carcinoma (MTC) possess tumor-initiating properties in vivo and exhibit differential responses to chemotherapeutic agents. We demonstrated that separated CD133+ cells from the human MTC cell line TT are enriched for tumor-initiating cells as demonstrated by tumor formation in vivo. Nevertheless, TT CD133+ cells do not exhibit increased chemoresistance in comparison to parental cells. However, when MTC xenotransplants were treated with the chemotherapeutic drug 5-fluorouracil (5FU) in vivo, CD133 expression increased in MTC cells.
RESULTS: This cell line, designated FTTiv isolated from the drug-exposed xenotransplants, exhibits a significantly different response to 5FU associated with the substantial change in the expression profile of genes involved in 5FU metabolism and drug resistance. Moreover, the CD133+ tumor-initiating subpopulation derived from these drug-exposed FTTiv cells is significantly more resistant to 5FU and retains the chemoresistant properties upon FTTiv culture propagation.
CONCLUSIONS: These data suggest that the chemoresistant phenotype and the CD133+ MTC subpopulation emerged in response to chemotherapy in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24073856      PMCID: PMC3949502          DOI: 10.1089/thy.2013.0277

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  53 in total

1.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

2.  Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties.

Authors:  Nalú Navarro-Alvarez; Eisaku Kondo; Hironobu Kawamoto; Wael Hassan; Takeshi Yuasa; Yasuhiro Kubota; Masayuki Seita; Hiroyuki Nakahara; Takahiro Hayashi; Yuriko Nishikawa; Reham A R A Hassan; Shahid M Javed; Hirofumi Noguchi; Shinichi Matsumoto; Shuhei Nakaji; Noriaki Tanaka; Naoya Kobayashi; Alejandro Soto-Gutierrez
Journal:  Cell Transplant       Date:  2010-06-29       Impact factor: 4.064

3.  Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine.

Authors:  Lucia Kucerova; Miroslava Matuskova; Kristina Hlubinova; Roman Bohovic; Lucia Feketeova; Pavol Janega; Pavel Babal; Martina Poturnajova
Journal:  Cancer Lett       Date:  2011-07-26       Impact factor: 8.679

Review 4.  5-Fluorouracil pharmacogenomics: still rocking after all these years?

Authors:  Mario Scartozzi; Elena Maccaroni; Riccardo Giampieri; Mirco Pistelli; Alessandro Bittoni; Michela Del Prete; Rossana Berardi; Stefano Cascinu
Journal:  Pharmacogenomics       Date:  2011-02       Impact factor: 2.533

Review 5.  Clinical review: The emerging cell biology of thyroid stem cells.

Authors:  Terry F Davies; Rauf Latif; Noga C Minsky; Risheng Ma
Journal:  J Clin Endocrinol Metab       Date:  2011-07-21       Impact factor: 5.958

6.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

Review 7.  Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development.

Authors:  Shu-Feng Zhou; Lin-Lin Wang; Yuan Ming Di; Charlie Changli Xue; Wei Duan; Chun Guang Li; Yong Li
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 8.  The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.

Authors:  Scott Bidlingmaier; Xiaodong Zhu; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2008-06-06       Impact factor: 4.599

9.  Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells.

Authors:  Wen Li; Ashley N Reeb; William A Sewell; George Elhomsy; Reigh-Yi Lin
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

10.  In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.

Authors:  Giovanni Zito; Pierina Richiusa; Alessandra Bommarito; Elvira Carissimi; Leonardo Russo; Antonina Coppola; Monica Zerilli; Vito Rodolico; Angela Criscimanna; Marco Amato; Giuseppe Pizzolanti; Aldo Galluzzo; Carla Giordano
Journal:  PLoS One       Date:  2008-10-28       Impact factor: 3.240

View more
  3 in total

1.  Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells.

Authors:  Shuzheng Song; Guoqing Pei; Yaqiong Du; Jugang Wu; Xiaochun Ni; Shoulian Wang; Bojian Jiang; Meng Luo; Jiwei Yu
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

Review 2.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

Review 3.  Utilization of lung cancer cell lines for the study of lung cancer stem cells.

Authors:  Yuyi Wang; Ming Jiang; Chi Du; Yang Yu; Yanyang Liu; Mei Li; Feng Luo
Journal:  Oncol Lett       Date:  2018-03-14       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.